Table 2

Demographic and disease characteristics from visit immediately before methotrexate reinitiation in patients who reinitiated methotrexate within 4 weeks of entry into the OLE and those who reinitiated at a later time point

Characteristic, mean±SDMTX use before week 4
MTX use after week 4
Age, years*50.0±15.852.2±16.4
RA duration, years*0.5±0.60.9±0.9
CRP (mg/dL)0.4±0.21.1±1.2
SJC (0–66 joints)1.4±3.03.8±5.7
TJC (0–68 joints)1.6±3.75.9±7.5
HAQ-DI (range, 0–3)0.2±0.20.5±0.7†
PGA (0–100 mm VAS)4.9±8.419.3±17.1
PtGA (0–100 mm VAS)6.6±8.419.8±26.0†
CDAI (0–76)13.0±13.517.6±16.7
  • *Baseline values.

  • †n=29.

  • CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28(CRP), 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Disability Index of the Health Assessment Questionnaire; MTX, methotrexate; OLE, open-label extension; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analog Scale.